

Curriculum Vitae

André K. D. Liem, M.D.

Business Address

Pacific Shores Medical Group
1043 Elm Avenue, Suite #104
Long Beach, CA 90813
Phone: (562) 590-0345
Fax: (562) 437-8139

Professional Accreditation

2009 Clinical Instructor UCLA, Department of Medicine
2007 Recertification, Medical Oncology, Diplomate American Board of Internal Medicine (157574)
2007 Recertification, Hematology, Diplomate American Board of Internal Medicine (157574)
2004 Recertification, Internal Medicine, Diplomate American Board of Internal Medicine (157574)
1997 Hematology, Diplomate American Board of Internal Medicine (157574)
1997 Medical Oncology, Diplomate American Board of Internal Medicine
1994 Internal Medicine, Diplomate American Board of Internal Medicine
1991 Educational Commission for Foreign Medical Graduates (457-327-5)
1991 Federal Licensing Examination (610225010)
1987 M.D., Radboud University Nijmegen, The Netherlands
1985 M.Sc. Medicine, Radboud University Nijmegen, The Netherlands

Licenses

1994 Medical board of California (A053159)
1997 DEA registration

Postgraduate Training

1994-1997 Hematology & Oncology Fellowship Program
University of California, Irvine Medical Center, Orange, California
1991-1994 Internal Medicine Residency Program
University of Connecticut Health Center, Farmington, Connecticut
1990-1990 Emergency Medicine Senior House Officer
Charing Cross Hospital, London, United Kingdom.
1989-1990 Internal Medicine Internship
Luton & Dunstable Hospital, Luton, United Kingdom
1988-1989 Surgical Internship (General Surgery & Urology)
St. Mary's Hospital, Portsmouth, United Kingdom

Work Experience

1999-Present Pacific Shores Medical Group
Medical Oncology Practice
1997-1999 Coast Hematology Oncology Associates, Long Beach, California
Medical Oncology Practice
1996-1997 Sunrise Medical Group, Orange, California
Urgent Care Clinic
1989-1989 Locum tenens in Internal Medicine and Surgery, United Kingdom

Curriculum Vitae

André K. D. Liem, M.D.

Clinical Research

- 2004-Present Research Director, Pacific Shores Medical Group
1996 Moloney Murine Leukemia Virus Ribozyme
University of California at Irvine, California
- 1987 Parasited Erythrocytes and Immunogenic Parasited Erthrocytes in
Plasmodium bergei.
Radboud University Nijmegen, The Netherlands
- 1987 Characterization of Glutamate Dehydrogenase and Ammonia in
Bacillus fastidiosus
Radboud University Nijmegen, The Netherlands
- 1985 T-cell receptor rearrangements in Mycosis Fungoides and Sézary
Syndrome.
British Columbia Cancer Research Centre, Vancouver, British
Columbia, Canada

Professional Development

- 1993 Adult and Pediatric Bone Marrow Transplant Unit
Fred Hutchinson Cancer Research Center, Seattle, Washington
- 1987-1988 Medical Biology
Accredited in applied statistics, immunology, computer programming,
clinical and immuno-toxicology
Radboud University Nijmegen, The Netherlands

Publications

Naeim, L. S. Lin, R. Dichmann, **A. K. D. Liem**, D. Chan, R. Patel, E. H. L. Hu, N. S. Tchekmedyian, Z. A. Wainberg, J. R. Hecht, TORI
Research Team: F. Kabbinar, H.J. Wang, and N. Ryba: Phase II
study of frontline capecitabine (CAP) and bevacizumab (BEV) in frail
and elderly patients with metastatic colorectal cancer (mCRC)
American Society of Clinical Oncology, GI symposium Abstr. #1611
Submitted July 2009

Saura C, Martin M, Moroosse R, Harb W, **Liem K**, Arena F, Gressler
V, Cortés J, Wade M, Powell C, Shapiro M: Safety of neratinib (HKI-
272) in combination with capecitabine in patients with solid tumors: a
phase 1/2 study. Poster San Antonia Breast Cancer Symposium), Dec
2009

Liem AK, Cheng H, Quan E, Ucar K, Al-Jazayrly G, Barton C, Cloo L,
Gabert T, Tchekmedyian S: Expanded access single institution clinical
program experience with ZD1839 (Iressa™) for patients with
advanced non-small cell lung cancer (NSCLC). Proc. of the American
Society of Clinical Oncology, Abstr. #2705, 2002.

Tchekmedyian NS, **Liem AKD**: A Patient with Metastatic Non-Small-
Cell Lung Cancer Treated with ZD1839. Case studies in lung cancer, a
Physicians' Education Resource publication, vol.1, no. 9, November

Curriculum Vitae

André K. D. Liem, M.D.

2002.

H. J. M. Op Den Camp, **K. D. Liem**, P. Meesters, J. M. H. Hermans and C. Van Der Drift: Purification and characterization of the NADP-dependent glutamate dehydrogenase from *Bacillus fastidiosus*.
Antonie van Leeuwenhoek 55:303-311 (1989)

Clinical Trials Experience (Selected)

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin bound Paclitaxel (nab-Paclitaxel or Abraxane) and Lapatinib (TYKERB®) in Women who have received no more than one prior chemotherapeutic regimen in the treatment of ErbB2 Overexpressing Metastatic Breast Cancer

A Phase II Study of Erlotinib and modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients with Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia

Phase 2, Open-label, Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma

Multicenter, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy

A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma

Phase 1b Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma

A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma

Curriculum Vitae

André K. D. Liem, M.D.

of the Pancreas

A randomized multicenter phase II trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere®) plus Prednisone in patients with metastatic hormone refractory prostate cancer

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients with Advanced Malignancies from Solid Tumors

Dr Liem CV 09-30-2009.doc